FDA Approves New Treatment for Pancreatic Cancer

The US Food and Drug Administration (FDA) has approved a new treatment for pancreatic cancer, daraxonrasib, marketed under the brand name Rasonque and produced by Revolution Medicines. In clinical trials, this treatment nearly doubled the overall survival time for patients. A late-stage clinical trial involving 500 patients indicated that those taking the daily pill had an average survival time of 13.2 months, compared to 6.6 months for those receiving chemotherapy. The FDA described the drug as providing a critical new option for patients facing a challenging and historically difficult-to-treat cancer. Daraxonrasib works by targeting and inhibiting the mutated KRAS gene, which is present in over 90% of pancreatic tumors and contributes to cancer progression. Annually, approximately 67,000 individuals in the US are diagnosed with pancreatic cancer, which has the highest mortality rate among major cancers, according to the American Cancer Society. The cancer is often diagnosed at an advanced stage, making treatment difficult; more than half of those diagnosed die within three months. The FDA granted daraxonrasib a 'Breakthrough Therapy' designation in 2025, which is given to treatments for serious conditions that require expedited review. The agency approved the drug six months ahead of the regulatory deadline due to its unprecedented results in a high unmet need area, as stated by Angelo de Claro, director of the agency's Oncology Center of Excellence. The most common side effects reported include rash, diarrhea, nausea, fatigue, and vomiting. About 44% of patients taking daraxonrasib experienced severe side effects, compared to 57.5% of those treated with chemotherapy in the trial. Former US Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer in December, is participating in a clinical trial for the drug and has reported a reduction in tumor size.